Last reviewed · How we verify
Ramipril, Amlodipine and Atorvastatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Ramipril, Amlodipine and Atorvastatin (Ramipril, Amlodipine and Atorvastatin) — Midas Pharma GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ramipril, Amlodipine and Atorvastatin TARGET | Ramipril, Amlodipine and Atorvastatin | Midas Pharma GmbH | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ramipril, Amlodipine and Atorvastatin CI watch — RSS
- Ramipril, Amlodipine and Atorvastatin CI watch — Atom
- Ramipril, Amlodipine and Atorvastatin CI watch — JSON
- Ramipril, Amlodipine and Atorvastatin alone — RSS
Cite this brief
Drug Landscape (2026). Ramipril, Amlodipine and Atorvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/ramipril-amlodipine-and-atorvastatin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab